English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Interaction between M.avium and HIV drugs is unavoidable in HIV patients as for an improved life expectancy of HIV patients, additional medications have to be administered along with HIV drugs. The anti-M.avium drug rifabutin and protease inhibitor, ritonavir are associated with significant drug interactions involving the cytochrome P450 (CYP) enzyme system. Little information is available on the role of various drug delivery strategies in alleviations of interactions between anti-M. avium and anti-HIV drugs. The purpose of the present study was to evaluate effect of encapsulation of rifabutin and ritonavir in PLGA nanoparticles on the already known drug interaction exhibited by these drugs.

bmc infectious diseases

Effect of nanoencapsulation on the phenomenon of drug interaction between anti-M.avium drug, rifabutin and anti-HIV drug, ritonavir by employing poly (lactide-co-glycolide) nanoparticles